Spectral Medical Inc.
TSX:EDT.TOMedical - Diagnostics & Research
-$0.02 today
- Market cap
- $306.00M
- Beta
- 0.23
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.13
Volume 0.02M
Average 0.06M
EDT.TO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Spectral Medical Inc.TSX: EDT.TO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of CA$1.62M rose 28.7% year over year, ahead of the -10.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 650.5% from the prior quarter. Over 3 fiscal years it compounded at +21.0% a year.
Context
- Stock-based compensation amounted to 86.8% of revenue in FY2025, up 13.5 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.7% holds above the trailing-twelve-month pace of -10.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
CAD · from the cash flow
- Latest · FY2025
- 2.12M CAD
- Year-over-year change
- +26.5%
- 4-year CAGR
- +13.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.12M | +26.5% |
| FY2024 | 2024-12-31 | 1.68M | +12.6% |
| FY2023 | 2023-12-31 | 1.49M | +24.3% |
| FY2022 | 2022-12-31 | 1.2M | -4.9% |
| FY2021 | 2021-12-31 | 1.26M | — |
Stock-Based Compensation vs competitors
How EDT.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.1% is the 7th highest of 8, against a peer median of +64.7%.
- Stock-based compensation amounts to 89.8% of revenue for EDT.TO, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.67M USD | +143.3% | +84.7% | — | |
| LTM Mar 2026 | CA$7.29M CAD | -36.7% | -24.4% | 2.3% | |
| LTM Mar 2026 | $7.23M USD | +54.8% | +18.6% | 14.1% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $5.55M USD | +98.0% | +9.0% | 29.6% |
| LTM Mar 2026 | CA$5.06M CAD | +220.3% | -44.8% | 1.6% | |
| LTM Mar 2026 | CA$4.35M CAD | +17.3% | +51.7% | 6.5% | |
| LTM Mar 2026 | CA$2.48M CAD | -10.1% | +21.0% | 89.8% | |
| LTM Mar 2026 | $1.8M USD | +64.7% | +62.8% | 3.5% | |
| Peer median (excluding EDT.TO) | — | +64.7% | +18.6% | 5.0% | |
Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.79M) | (11.25M) | (15.66M) | (15.4M) | (47.69M) |
| Depreciation & Amortization | 294K | 272K | 218K | 251K | 250K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.26M | 1.2M | 1.49M | 1.68M | 2.12M |
| Change in Working Capital | (1.76M) | 579K | (406K) | 1.01M | (189K) |
| Accounts Receivables | 55K | (877K) | 870K | (265K) | 246K |
| Inventory | (51K) | (47K) | (26K) | 137K | (148K) |
| Accounts Payables | (1.11M) | 1.65M | (267K) | (51K) | (265K) |
| Other Working Capital | (656K) | (142K) | (983K) | 1.19M | (22K) |
| Other Non-Cash Items | 288K | (698K) | 3.64M | 3.64M | 33.88M |
| Operating Cash Flow | (8.7M) | (9.9M) | (10.72M) | (8.82M) | (9.52M) |
| Capital Expenditures | (483K) | (33K) | (185K) | (27K) | (195K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 158K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (325K) | (33K) | (185K) | (27K) | (195K) |
| Debt Repayment | (113K) | 3.71M | 3.93M | 9.74M | 9.67M |
| Common Stock Issued | 10M | 4.03M | 0 | 1.15M | 3.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.28M | 1.72M | 1.51M | (2.02M) | (155K) |
| Financing Cash Flow | 12.17M | 9.46M | 5.44M | 8.88M | 12.91M |
| Effect of Forex Changes | (56K) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.08M | (476K) | (5.46M) | 36K | 1.08M |
| Free Cash Flow | (9.18M) | (9.93M) | (10.91M) | (8.85M) | (9.72M) |
Spectral Medical Inc.
TSX:EDT.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.